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Development and progression of breast cancer is associated with
the accumulation of genetic changes involving oncogenes, tumour
suppressor genes and several other genes. In breast cancer, gene
amplifications often involve ERBB2 (at 17q12), cyclin-D1 (11q13)
and MYC (8q24). In addition, other genes, such as FGFR1 (8p11),
(10q25) and IGFR1 (15q25) may also undergo amplification
(Devilee et al, 1994). Recently, numerous additional chromosomal
regions of increased copy number, such as 17q23 and 20q13, have
been reported by comparative genomic hybridization (CGH) and
microdissection (Guan et al, 1994; Kallioniemi et al, 1994; Tanner
et al, 1994). These loci may also harbour genes with an important
role in breast cancer progression. In a similar fashion, mutations or
inactivations of several tumour suppressor genes, such as p53, p16
and RB1, have been reported (Devilee et al, 1994; Geradts et al,
1996; Li et al, 1997), but loss of heterozygosity and CGH analyses
suggest several other chromosomal regions, such as 1p, 3p, 6q, 8p
and 16q (Devilee et al, 1994), where additional putative tumour
suppressor genes may reside. Overall, many chromosomal regions
appear to be involved in breast cancer development and progres-
sion, but in most cases, the genes implicated in these rearrange-
ments remain unknown.
Cancer cell lines provide an important resource for cancer gene
discovery as well as for functional studies. Several breast cancer
cell lines exist, but information on their origin, as well as their
genetic and molecular characteristics are very fragmentary. Over
the past several years, our laboratory has developed and optimized
methods for the culture of normal human mammary epithelial cells
of the luminal lineage (Ethier et al, 1990, 1993). We have also
established a panel of 11 SUM-human breast cancer cell lines,
which are maintained continuously in the laboratory. The estab-
lishment of some of these cell lines, including SUM-44, SUM-52,
and SUM-102 has been described previously (Ethier et al, 1993,
1996; Sartor et al, 1997). In addition, studies on Stat3 activation
and focal adhesion kinase activation in human breast cancer cells
that made use of the above lines, as well as the SUM-149, SUM-
1315, SUM-159, SUM-185 and SUM-190 cell lines, have been
presented elsewhere (Garcia et al, 1997; Flanagan et al, 1999;
Ignatoski et al, 1999).
Here, we performed a molecular cytogenetic survey of genetic
changes by CGH to study to what extent these 11 cell lines
resemble primary human breast carcinomas, as well as to evaluate
whether these cell lines contain characteristic genetic changes that
could facilitate cancer gene discovery.
MATERIALS AND METHODS
Isolation and culture of human breast cancer cell lines
The isolation and culture of cell lines designated SUM-44, SUM-
52 and SUM-102 have been described in detail (Ethier et al, 1993,
1996; Sartor et al, 1997). More recently, our laboratory has devel-
oped seven other human breast cancer cell lines from primary
tumours (PT), chest wall recurrences (CWN) and pleural effusion
(PE) metastases (Table 1). In addition, one cell line was developed
from a highly invasive breast cancer specimen that had been
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grown for two transplant generations in immunodeficient mice
(MO2) before being explanted into culture. The cells derived from
these xenografts were kindly provided by Dr D Schwartzentruber of
the Surgery Branch, NCI. The newly developed cell lines have been
designated: SUM-149, SUM-1315, SUM-159, SUM-185, SUM-
190, SUM-206, SUM-225 and SUM-229. SUM-149 and SUM-190
were derived from patients with inflammatory breast cancer.
Nine of the 11 patients had received chemotherapy prior to
sampling. All cell lines are immortal, and express luminal cyto-
keratins consistent with their origin from luminal breast epithelial
cells. The cell lines were isolated and grown in a variety of media
that were previously optimized for the culture of normal human
breast epithelial cells (Mahacek et al, 1993; Ethier et al, 1996). All
culture media were prepared from a base medium of Ham’s F-12
(Table 1). Some media were supplemented with 5% fetal bovine
serum (FBS). Serum-free media were supplemented with 0.1%
bovine serum albumin (BSA), sodium selenite, 3,3¢,5-triiodo-L-
thyronine, transferrin and ethanolamine as previously described
(Ethier et al, 1993, 1996; Sartor et al, 1997). Several of the cell
lines (SUM-52, 149, 159, 185, 225 and 229) were routinely
cultured in Ham’s F-12 supplemented with 5% FBS, insulin
(5 mg ml–1) and hydrocortisone (1 mg ml–1, 5% IH medium). SUM-
1315 cells were cultured in serum-free medium with insulin and
EGF (10 ng ml–1). SUM-190 cells were routinely cultured in
serum-free medium with insulin and hydrocortisone, but were
originally isolated in a more complex medium supplemented
with epidermal growth factor (EGF) and lysophosphatidic acid
(10 mM), the latter of which was required for initial growth of the
cells. SUM-206 cells were cultured in 5% IH medium supplemented
with progesterone (100 ng ml–1). These cells, like
SUM-102 cells described previously (Sartor et al, 1997), were
responsive to exogenous progesterone for in vitro growth. Thus, this
panel of human breast cancer cell lines showed different require-
ments for exogenous hormones and growth factors (Table 1).
All 11 breast cancer cell lines isolated were immortal in culture,
and were karyotypically abnormal. Information on the in vitro
morphology and karyotype of the cell lines can be found
at http://p53.cancer.med.umich.edu/clines/clines.html. Detailed
methods for the growth of each of these cell lines can be found at
http://p53.cancer.med.umich.edu/clines/elab/ethier.html. In addi-
tion, these cells uniformly expressed the luminal cytokeratins 8
and 18, and all cell lines except the SUM-102 line expressed
keratin 19 as determined by immunocytochemistry.
Comparative genomic hybridization
CGH was carried out on the 11 breast carcinoma cell lines essen-
tially as described previously (Karhu et al, 1997; Tirkkonen et al,
1998) with some modifications. Briefly, genomic cell line (test)
and normal female (reference) DNAs were labelled by nick
translation incorporating either SpectrumGreen or SpectrumRed
dUTPs (Vysis Inc., Downers Grove, IL, USA). Two hundred
nanograms of green-labelled cell line DNA, 100 ng of red-labelled
normal reference DNA, and 10 mg of unlabelled Cot-1 DNA were
hybridized to denatured normal peripheral blood metaphase slides.
After a 2-day hybridization at 37°C, the slides were washed and
counterstained with DAPI in an antifade medium. Image acquisi-
tion was performed with a digital image analysis system using a
Zeiss Axiophot microscope and a Photometrics CCD camera. The
system was controlled by the IPLab Spectrum software for Power-
Macintosh. After acquisition of digital images on wavelengths
matching the DAPI, SpectrumGreen and SpectrumRed emissions,
green to red ratio profiles were quantitated with Quips XL
program (Vysis Inc.). Green and red intensities were normalized so
that the average green to red ratio in each metaphase was set to 1.0.
Normal male versus female hybridizations were used as negative
controls, and for ensuring the linearity of the hybridization (Karhu
et al, 1997). MPE-600 breast cancer cell line with known aberra-
tions was used as a positive control. Chromosomal regions where
CGH ratios exceeded 1.2 were considered as gained, and those
regions where the ratio was less than 0.8 as lost. High-level ampli-
fications were defined as small regions (1–3 chromosomal bands
wide) with highly elevated ratio (ratio > 1.4). In the case of very
small regions of amplification, the average ratio profile from
multiple metaphases may not reach this cut-off value, since the
peak ratio may take place at different locations in the different
metaphases as a result of the non-linear stretching of metaphase
chromosomes. Therefore, ratio cut-offs were evaluated from
individual profiles (low-level amplification).
Fluorescent in situ hybridization
Dual colour fluorescent in situ hybridization (FISH) analysis was
done on interphase and metaphase slides prepared from the cell
lines as described before (Tanner et al, 1994). To facilitate FISH
analysis of interphase nuclei, multi-spot slides were made, each
containing nuclei from all the 11 cell lines. The slides were
Table 1 Preparation of the SUM breast cancer cell lines: origin of the tissue, prior chemotherapy given to the patients, and media requirements for sustained in
vitro growth
Cell line Breast cancer specimen Prior Media
chemotherapy supp.a
SUM-44PE Pleural effusion + SFIH
SUM-52PE Pleural effusion + 5%IH
SUM-102PT Intraductal carcinoma/micro-invasion + SFIHE
SUM-1315M02 Skin metastasis of inflitrating ductal carcinoma + SFIE
SUM-149PT Invasive ductal carcinoma (inflammatory) + 5%IH
SUM-159PT Anaplastic carcinoma – 5%IH
SUM-185PE Pleural effusion + 5%IH
SUM-190PT Invasive ductal breast carcinoma (Inflammatory) + SFIH
SUM-206CWN Chest wall recurrence of invasive ductal carcinoma + 5%IHP
SUM-225CWN Chest wall recurrence of ductal carcinoma in situ – 5%IH
SUM-229PE Pleural effusion + 5%IH
a5%, 5% fetal bovine serum; SF, serum-free; I, insulin; H, hydrocortisone; E, epidermal growth factor, P, progestrone.1330 F Forozan et al
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Figure 1 Summary ideogram of gains (right) and losses (left) of chromosomal regions seen by CGH in 11 SUM breast cancer cell lines. Black boxes represent
regions of high level amplification by CGH, and open boxes other small regions of low level amplificationMolecular cytogenetic analysis of breast cancer cell lines 1331
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hybridized with SpectrumOrange labelled probes for cyclin-D1,
ERBB2, and MYC with the corresponding SpectrumGreen-labelled
centromeric probe for chromosomes 11, 17 and 8 as reference
probes (Vysis Inc.). Since the cell lines were genetically rather
homogeneous, we scored 20 non-overlapping nuclei with intact
morphology based on DAPI counterstaining to determine the
mean copy number of the gene probes per cell as well as the copy
number relative to the chromosome specific reference probe.
Greater than three-fold increase in the copy number of the test
probe over that of the reference probes was considered to represent
significant gene amplification.
Southern blot
For Southern blot analysis, genomic DNA was isolated from
confluent monolayers of cells. Fifteen micrograms of EcoRI- or
HindIII-digested DNA was loaded onto 0.8% agarose gels,
separated by electrophoresis and transferred onto Immobilon-N
membrane (Millipore Corp., Bedford, MA, USA). Ethidium
bromide-stained agarose gels were photographed prior to transfer
to ensure equal loading of the gel. The transfer membrane was UV-
cross-linked, prehybridized overnight and then hybridized
with32P-labelled probes specific for FGFR1 and FGFR2. The
specific activity of the probes was always greater than 1 ´ 108 cpm
ml–1. Hybridization proceeded at 37°C for 24 h. Following
hybridization, the membrane was washed twice in 2 ´ standard
saline citrate (SSC), 0.2% sodium dodecyl sulphate (SDS) for 10
min at room temperature, once in 1 ´ SSC, 0.2% SDS for 15 min
at room temperature, and once in 0.5 ´ SSC, 0.2% SDS for 20 min
at 50°C. The membrane was then exposed to X-ray film for auto-
radiography.
RESULTS
Gains and losses of DNA sequences by CGH
All 11 breast cancer cell lines displayed copy number alterations
by CGH as expected based on the presence of abnormal karo-
types in G-banding analysis. There were, on average, 14 genetic
changes in each cell line (range from 4 to 29) with 6 losses (range
from 0 to 14) and 8 gains (range 3 to 15) per cell line. A summary
of the different regions of gains and losses is shown in an
ideogram format in Figure 1. The minimal common regions for the
most frequent copy number gains were: 8q22–q24.1 (73% of the
cases), 1q32 (64%), 7q21–q22 (64%), 3q24–q29 (45%) and
7p12–p21 (45%). The most common losses were: Xcen-p11.3
(54%), 8p22–p23 (45%), 18q12–q22 (45%), and Xq24–q25 (45%)
(Table 2).
Most of the gains of DNA sequence copy number were of low
magnitude and affected large regions. However, many cell lines
also displayed informative small, localized regions of increased
DNA sequence copy numbers, often of considerable magnitude
(ratios from 1.4 to 2.1). Since these may pinpoint locations of
important genes, we performed a separate analysis of such local-
ized copy number increases.
DNA amplifications of known oncogene loci
Many of the amplifications seen by CGH-affected chromosomal
regions where genes, previously shown to be amplified in breast
cancer, reside. These regions included the ERBB2 locus at 17q12,
MYC at 8q24.1, cyclin-D1 at 11q13, FGFR1 at 8p12, and FGFR2
at 10q25. Amplifications of these five genes were tested using
specific probes by FISH (ERBB2, MYC, Cyclin-D1) (Figure 2) or
Southern blot (for FGFR1 and FGFR2) as summarized in Table 3.
With the exception of the MYC locus (see below), a peak in the
CGH profile at these chromosomal sites reflected a high-level
amplification of the known target genes at these chromosomal
regions. For example, SUM-52 cells had very prominent peaks
by CGH at 8p11–p12 and at 10q24–q25, and Southern analysis
confirmed high-level amplifications of both FGFR1 and FGFR2.
As expected, analyses with specific probes also revealed amplifi-
cations that did not result in a peak of ratio profiles in CGH. A
high level amplification of ERBB-2 in the SUM-225 cell line did
not lead to a significant increase of the copy number ratio at
17q12.
Table 2 Most common gains and losses in the SUM panel of breast cancer
cell lines by CGH
Gains Losses
Chromosome region (%) Chromosome region (%)
8q (q22–q24.1)a 73 Xp (cen-p11.3) 54
1q (q32) 64 8p (p22–p23) 45
7q (q21–q22) 64 18q (q12–q22) 45
3q (q24–q29) 45 Xq (p24–p25) 45
7p (p12–p21) 45 10q (q22–q26) 36
5q (q11.2–q12) 36 11q (q23–q25) 36
2p (p21) 27 13q (q21–q22) 36
11p (cen-p14) 27 13q (q32–q34) 36
11q (q13) 27 18p 36
15q (q15) 27 4p (p14–p16) 27
20q (q13) 27 3p (p12) 27
Xq (q27–q28) 27 3p (p13–p14) 27
6q (q21–q27) 27
17p 27
aThe minimal common chromosomal region of involvement is indicated in
parenthesis
ERBB2
Cyclin-D1
CGH
CGH
FISH
FISH
SUM-190
Figure 2 Detection of amplifications of the ERBB2 and cyclin-D1 genes in
the SUM panel of breast cancer cell lines by CGH and FISH. SUM-190 had
both ERBB2 and cyclin-D1 gene amplification. The same amplifications were
visible as increased green fluorescent intensity at 17q12 and 11q13 by CGH
and as increased number of signals in interphase FISH. The ERBB2 and
cyclin-D1 probes were visualized in the cell line nuclei in red colour, whereas
the corresponding chromosome centromere probes (for chromosomes
17 and 11 respectively) were visualized in green colourDNA amplifications at other chromosomal loci
CGH analysis of the 11 breast cancer cell lines also resulted in the
detection of several sites of highly increased DNA sequence copy
number in regions not known to harbour breast cancer oncogenes
(Figure 3). Up to 69% of all DNA amplifications were localized at
such ‘new’ regions of amplification. These regions included
1q41–q43, 7q21–q22, 7q31, 8q23, 9p21–p23, 11p12–p14,
15q12–q14, 16q13–q21, 17q23, 20p11–12, and 20q13. Gain of 8q
was the most common abnormality seen by CGH, and in four
cases high-level amplifications were seen (SUM-225, 229, 159,
206). The minimal region of amplification was at 8q22–q23,
slightly proximal to the MYC locus at 8q24.1. In agreement with
this observation, none of the cell lines displayed high-level ampli-
fications of MYC by FISH. However, SUM-159 and SUM-225 did
have approximately twofold increases of MYC copy number as
determined by FISH.
DISCUSSION
The data presented here on the genetic changes of the 11 newly
established breast cancer cell lines provide a useful resource and
starting point for discovery of novel cancer genes and signalling
pathways. Several observations indicate that these cell lines
resemble primary human breast cancers. First, CGH analyses
revealed several recurrent chromosomal gains, such as those at 1q,
3q and 8q, that are also very common in uncultured breast cancers
(Ried et al, 1995; Kuukasjarvi et al, 1997; Tirkkonen et al, 1998).
Second, many of the losses of chromosomal regions in these cell
lines, such as those at 3p, 6q, 8p, 11q, 13q, 17p, 18q and X, have
also been previously implicated in both LOH (Devilee et al, 1994)
and CGH studies (Ried et al, 1995; Kuukasjarvi et al, 1997;
Tirkkonen et al, 1998) of primary breast cancer specimens. Third,
the spectrum and frequency of amplifications involving the known
oncogene loci (ERBB2, cyclin-D1, FGFR1 and FGFR2) in these
cell lines were similar to those previously reported for uncultured
human breast cancers (Adnane et al, 1991; Devilee et al, 1994).
The CGH data indicated the presence of several characteristic
high level DNA amplifications in these cell lines. The majority of
these involved chromosomal sites distinct from those of known
oncogenes. DNA amplification is known to be a predominant
mechanism for oncogene activation in many solid tumours. It can
be suspected that the other regions found here also contain genes
that are important in the development and progression of breast
cancer. This issue is supported by recent molecular studies of the
20q region, the only amplification site discovered by CGH that has
so far been extensively studied. Many potential target genes,
including serine-threonine kinase BTAK/Aurora II (Sen et al,
1997; Bischoff et al, 1998), steroid receptor co-activator AIB1
(Anzick et al, 1997), MYBL2 oncogene (Kononen et al, 1998)
PTPN1 phosphotyrosine phosphorylase (Tanner et al, 1996), as
well as ZNF217 and NABC1 (Collins et al, 1998) genes have been
found to be involved in DNA amplifications at 20q.
1332 F Forozan et al
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Table 3 Amplification of known oncogenes in the SUM panel of breast
cancer cell lines
Cell line Cyclin-D1 c-MYC ERBB2 FGFR1 FGFR2
SUM-44 + – – + –
SUM-52 + – – + +
SUM-102 – – – – –
SUM-1315 – – – – –
SUM-149 – – – – –
SUM-159 – – – – –
SUM-185 – – – – –
SUM-190 + – + – –
SUM-206 – – – – –
SUM-225 – – + – –
SUM-229 – – – – –
The + and – signs represent the presence or absence of amplification,
respectively, detected by FISH (for cyclin-D1, c-MYC, and ERBB2) or
Southern (for FGFR1 and FGFR2).
SUM-52 SUM-149
n=15
7
n=12
7
SUM-149 SUM-149 SUM-149 SUM-149 SUM-44
n=16
9
n=15
11
n=15
15
n=14
16
n=16
20
SUM-52 SUM-206
n=14
8
n=14
8
Figure 3 Examples of CGH profiles illustrating prominent gains and amplifications involving chromosomal sites such as 7q21–q22, 7q31, 8q23, 9p21–p23,
11p12–p14, 15q12–q14, 16q13–q21 and 20p11–p12. The green to red fluorescent intensity profiles are shown along with ± 1 s.d. For each profile, the vertical
line in the middle is the ratio value of 1.0, the line to the left represents a ratio cut-off value of 0.8, and the line to the right 1.2. Chromosome ideograms
displayed next to the profile have regions of gain (right) and loss (left) marked as barsAmplification sites that were seen in this panel of cell lines, and
where candidate genes have not been defined include 7q21–q22,
7q31, 8q23, 15q12–q14, 16q13–q21 and 17q23 (Figure 3). It is
likely that these sites are also of importance to breast cancer
progression and harbour new candidate genes. Many of these
amplifications, such as 7q31, often also appear in vivo in uncul-
tured cancers affecting organs other than breast, such as brain
(Wullich et al, 1993; Fischer et al, 1995) and gastric cancer
(Houldsworth et al, 1990). The 8q23–q24 chromosomal region
was the most common site of increased copy number in this panel
of cancer cell lines and was present in eight of the 11 cell lines.
Many gains involved the whole chromosome arm, but there were
also several localized increases of copy number at 8q23, a site
slightly proximal to the MYC oncogene locus at 8q24.1. Since
FISH analyses indicated only a twofold increase of the copy
number of MYC in two cell lines, and no increase in any of the
other ones, it is likely that genes other than MYC are the primary
targets for the selection of 8q gains and 8q23–q24 amplifications
in these cells. Further studies of this chromosomal site are impor-
tant, as gain of the 8q arm is one of the most common genetic
aberrations in breast cancer and several other tumour types
(Forozan et al, 1997).
These results show that this panel of breast cancer cell lines
could be useful for identification of cancer genes from the recur-
rent sites of chromosomal aberrations mapped in this study. In
addition, they may facilitate studies of growth regulatory mecha-
nisms that distinguish breast cancer cells from normal human
breast epithelial cells.
Overall, these phenotypically and genetically characterized cell
lines may serve as a starting point for the discovery of previously
unknown signalling pathways, as well as help in the functional
analysis of known signal transduction pathways operative in
human breast cancer cells. In addition, several high-level amplifi-
cation sites in these cell lines are likely to be useful as a starting
point for cancer gene discovery.
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